Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71

Archives of Virology

Volumn 157, Issue 1, 2012, Pages 37-41

  Mao, Qunying ^a   Li, Nan ^b   Yu, Xiang ^b   Yao, Xin ^a   Li, Fengxiang ^a   Lu, Fengmin ^c   Zhuang, Hui ^c   Liang, Zhenglun ^a   Wang, Junzhi ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b Hualan Biological Engineering Inc   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL; ARTICLE; CHINA; CROSS PROTECTION; ENTEROVIRUS; GENETICS; GUINEA PIG; HAND FOOT AND MOUTH DISEASE; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MOUSE; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CHINA; CROSS PROTECTION; ENTEROVIRUS A, HUMAN; GUINEA PIGS; HAND, FOOT AND MOUTH DISEASE; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

ANIMALIA; HUMAN ENTEROVIRUS 71; MUS;

EID: 84855336465     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1136-3     Document Type: Article

References (20)

1. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304-309.
2. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT (2007) An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77: 188-191.
3. National notifiable diseases announced by Ministry of Health of the People's Republic of china. http://www. moh. gov. cn/publicfiles/business/htmlfiles/wsb/pyqxx/list. htm.
4. (2009) Antigenic and genetic characteristics of H5N1 viruses and candidate vaccine viruses developed for potential use in human vaccines, February 2009. Wkly Epidemiol Rec 84: 72-76.
5. Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9: 149-156.
6. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.
7. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
8. Yao X, Mao QY, Huang WJ, He P, Zhou C, Zhang W, Liang ZL, Li FX, Wang JZ (2009) Genetic characterization of enterovirus 71 complete genome isolated in Beijing, 2008. Zhonghua Liu Xing Bing Xue Za Zhi 30: 729-732.
9. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, An HQ, Li DX, Wang SW, Xu AQ, Wang ZJ, Xu WB (2009) An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 44: 262-267.
10. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, Hongo S, Sugawara K, Shimizu H, Ahiko T (2009) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27: 3153-3158.
11. van der Sanden S, van der Avoort H, Lemey P, Uslu G, Koopmans M (2010) Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses. J Gen Virol 91: 1949-1958.
12. Mao QY, He P, Yu X, Li N, Hao CS, Gao Q, Dong CH, Liang ZL, Li FX, Shen XL, Wang JZ (2010) Laboratory evaluation of method for determination of neutralizing antibody against human enterovirus. Chin J Biologicals 23: 885-888.
13. Gomes Mde L, de Castro CM, Oliveira MJ, da Silva EE (2002) Neutralizing antibodies to enterovirus 71 in Belem, Brazil. Mem Inst Oswaldo Cruz 97: 47-49.
14. Kargar M, Sadeghipour S, Nategh R (2009) Environmental surveillance of non-polio enteroviruses in Iran. Virol J 6: 149.
15. Saeed M, Zaidi SZ, Naeem A, Masroor M, Sharif S, Shaukat S, Angez M, Khan A (2007) Epidemiology and clinical findings associated with enteroviral acute flaccid paralysis in Pakistan. BMC Infect Dis 7: 6.
16. Saraswathy TS, Khairullah NS, Sinniah M, Fauziah MK, Apandi MY, Shamsuddin M (2004) Laboratory acute flaccid paralysis surveillance in Malaysia: a decade of commitment to the WHO global polio eradication initiative. Southeast Asian J Trop Med Public Health 35: 421-424.
17. WHO/EPI/CDS/POLIO/90. 01 (1997) Manual for the virological investigation of poliomyelitis. http://whqlibdoc. who. int/hq/1997/WHO_EPI_GEN_97. 01. pdf.
18. Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC (2006) Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12: 921-927.
19. Ong KC, Devi S, Cardosa MJ, Wong KT (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661-665.
20. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.